Kloke H J, Wetzels J F, Koene R A, Huysmans F T
Department of Medicine, University Hospital, Nijmegen, The Netherlands.
Nephrol Dial Transplant. 1998 Mar;13(3):646-50. doi: 10.1093/ndt/13.3.646.
The observation that proteinuria is an important determinant of the progression of renal disease has prompted numerous studies on the effects of antihypertensive agents on protein excretion. Reports on the proteinuric effects of calcium-channel blockers are quite controversial. It has been suggested that the short-acting dihydropyridine calcium-channel blocker nifedipine increases protein excretion by interference with tubular protein reabsorption.
In a randomized controlled trial 10 patients with renal disease and proteinuria were treated with a dose of 10 mg nifedipine o.d. (slow release formulation) for 1 week. The acute effects on renal and systemic haemodynamics and on urinary albumin, IgG, and beta2-microglobulin excretion were investigated during a clearance study in the supine position after the first dose. After 1 week of treatment urinary protein excretion rates were measured in 24-h urine samples collected in the ambulatory patient in consecutive fractions of 4-8 h during normal daily activities.
After the first dose nifedipine lowered mean arterial blood pressure in the supine position by 7+/-1 mmHg (<0.01), attenuated proximal tubular sodium reabsorption (fractional excretion of sodium 3.48+/-0.49 vs 2.62+/-0.35% during control, P<0.02), but did not affect proximal tubular protein reabsorption (fractional urinary excretion of beta2-microglobulin 0.97+/-0.30 vs 0.98+/-0.32% during control, NS). The decrease in blood pressure was not accompanied by decreases in urinary albumin or IgG excretion rates. The selectivity index as well as GFR, RPF, and FF did not change. Continued treatment for 1 week with nifedipine did not influence 24-h protein excretion. However, we observed a rise of proteinuria during daily activities in the first 4 h after drug intake compared to the start of the study with the patients in supine position. During control measurements there was a slight increase in proteinuria. During nifedipine the increase in proteinuria was more marked and correlated with the selectivity index.
(1) Nifedipine 10 mg orally did not impair tubular protein reabsorption. (2) Nifedipine had no immediate antiproteinuric effect despite the observed blood pressure reduction. (3) Nifedipine increased proteinuria in ambulatory urine collections. This latter observation might explain the seemingly different effects of dihydropyridine calcium-channel blockers as reported in previous studies.
蛋白尿是肾脏疾病进展的重要决定因素这一观察结果促使人们对降压药对蛋白质排泄的影响进行了大量研究。关于钙通道阻滞剂对蛋白尿的影响的报道颇具争议。有人提出,短效二氢吡啶类钙通道阻滞剂硝苯地平通过干扰肾小管对蛋白质的重吸收来增加蛋白质排泄。
在一项随机对照试验中,10例患有肾脏疾病和蛋白尿的患者接受每日10mg硝苯地平(缓释制剂)治疗,为期1周。在首剂给药后,于仰卧位进行清除率研究期间,调查其对肾脏和全身血流动力学以及尿白蛋白、IgG和β2-微球蛋白排泄的急性影响。治疗1周后,在日常活动期间,收集门诊患者连续4 - 8小时的24小时尿液样本,测量尿蛋白排泄率。
首剂给药后,硝苯地平使仰卧位平均动脉血压降低7±1mmHg(<0.01),减弱近端肾小管钠重吸收(钠分数排泄率在对照期间为3.48±0.49%,而用药后为2.62±0.35%,P<0.02),但不影响近端肾小管蛋白质重吸收(β2-微球蛋白尿分数排泄率在对照期间为0.97±0.30%,用药后为0.98±0.32%,无显著性差异)。血压下降并未伴随尿白蛋白或IgG排泄率降低。选择性指数以及肾小球滤过率、肾血浆流量和滤过分数均未改变。硝苯地平持续治疗1周未影响24小时蛋白质排泄。然而,与研究开始时患者仰卧位相比,我们观察到在服药后的前4小时日常活动期间蛋白尿增加。在对照测量期间蛋白尿有轻微增加。服用硝苯地平时蛋白尿增加更明显,且与选择性指数相关。
(1)口服10mg硝苯地平不损害肾小管蛋白质重吸收。(2)尽管观察到血压降低,但硝苯地平没有立即的抗蛋白尿作用。(3)硝苯地平增加了门诊尿液收集时的蛋白尿。后一观察结果可能解释了先前研究中报道的二氢吡啶类钙通道阻滞剂看似不同的作用。